share_log

Affimed Analyst Ratings

Affimed Analyst Ratings

經確認的分析師評級
Benzinga ·  2023/09/12 08:59
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/12/2023 1300% Cantor Fitzgerald → $7 Reiterates Overweight → Overweight
09/07/2023 1300% Cantor Fitzgerald → $7 Reiterates Overweight → Overweight
08/11/2023 1100% Truist Securities $8 → $6 Maintains Buy
08/11/2023 900% HC Wainwright & Co. → $5 Reiterates Buy → Buy
08/08/2023 1100% Berenberg → $6 Assumes → Buy
06/05/2023 900% HC Wainwright & Co. $6 → $5 Maintains Buy
05/24/2023 1100% HC Wainwright & Co. → $6 Reiterates Buy → Buy
03/27/2023 1300% Wells Fargo → $7 Assumes → Overweight
03/24/2023 100% Stifel $2 → $1 Maintains Hold
03/24/2023 1100% HC Wainwright & Co. → $6 Reiterates → Buy
12/12/2022 1300% Wells Fargo $8 → $7 Maintains Overweight
12/12/2022 1100% Piper Sandler $7 → $6 Maintains Overweight
12/12/2022 1100% SVB Leerink $10 → $6 Maintains Outperform
12/12/2022 1100% HC Wainwright & Co. → $6 Initiates Coverage On → Buy
10/10/2022 300% Stifel $9 → $2 Downgrades Buy → Hold
06/23/2022 1700% SVB Leerink $10 → $9 Maintains Outperform
03/31/2022 1300% Piper Sandler → $7 Initiates Coverage On → Overweight
02/23/2022 2300% Cantor Fitzgerald → $12 Initiates Coverage On → Overweight
10/21/2021 1900% Truist Securities → $10 Initiates Coverage On → Buy
10/12/2021 2300% SVB Leerink $13 → $12 Maintains Outperform
09/30/2021 2300% Stifel → $12 Initiates Coverage On → Buy
03/31/2021 2900% Credit Suisse → $15 Initiates Coverage On → Outperform
03/24/2021 2900% Wells Fargo $10 → $15 Maintains Overweight
03/11/2021 2700% SVB Leerink $9 → $14 Maintains Outperform
11/11/2020 1700% SVB Leerink $8 → $9 Maintains Outperform
06/24/2020 1500% SVB Leerink $7 → $8 Maintains Outperform
03/28/2019 1500% SVB Leerink → $8 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/12/2023 1300% 康託·菲茨傑拉德 →$7 重申 超重→超重
09/07/2023 1300% 康託·菲茨傑拉德 →$7 重申 超重→超重
2023年08月11日 1100% Truist證券 $8→$6 維護
2023年08月11日 900% HC Wainwright公司 →$5 重申 購買→購買
2023/08/08 1100% 貝倫伯格 →$6 假設 →購買
06/05/2023 900% HC Wainwright公司 $6→$5 維護
2023年05月24日 1100% HC Wainwright公司 →$6 重申 購買→購買
03/27/2023 1300% 富國銀行 →$7 假設 →超重
03/24/2023 100% Stifel $2→$1 維護 保持
03/24/2023 1100% HC Wainwright公司 →$6 重申 →購買
2022年12月12日 1300% 富國銀行 $8→$7 維護 超重
2022年12月12日 1100% 派珀·桑德勒 $7→$6 維護 超重
2022年12月12日 1100% SVB Leerink $10→$6 維護 跑贏大盤
2022年12月12日 1100% HC Wainwright公司 →$6 開始承保 →購買
2022年10月10日 百分之三百 Stifel $9→$2 評級下調 購買→Hold
2022/06/23 1700% SVB Leerink $10→$9 維護 跑贏大盤
03/31/2022 1300% 派珀·桑德勒 →$7 開始承保 →超重
02/23/2022 2300% 康託·菲茨傑拉德 →$12 開始承保 →超重
2021/10/21 1900% Truist證券 →$10 開始承保 →購買
10/12/2021 2300% SVB Leerink $13→$12 維護 跑贏大盤
09/30/2021 2300% Stifel →$12 開始承保 →購買
03/31/2021 2900% 瑞士信貸 →$15 開始承保 →跑贏大盤
03/24/2021 2900% 富國銀行 $10→$15 維護 超重
03/11/2021 2700% SVB Leerink $9→$14 維護 跑贏大盤
11/11/2020 1700% SVB Leerink $8→$9 維護 跑贏大盤
06/24/2020 1500% SVB Leerink $7→$8 維護 跑贏大盤
2019/03/28 1500% SVB Leerink →$8 開始承保 →跑贏大盤

What is the target price for Affimed (AFMD)?

阿基米德(AFMD)的目標價是多少?

The latest price target for Affimed (NASDAQ: AFMD) was reported by Cantor Fitzgerald on September 12, 2023. The analyst firm set a price target for $7.00 expecting AFMD to rise to within 12 months (a possible 1300.00% upside). 15 analyst firms have reported ratings in the last year.

康託·菲茨傑拉德於2023年9月12日報道了Affimed(納斯達克代碼:AFMD)的最新目標價。這家分析公司將目標價定為7美元,預計AFMD將在12個月內上漲(可能上漲1300.00%)。過去一年,有15家分析公司公佈了評級。

What is the most recent analyst rating for Affimed (AFMD)?

AFMD的最新分析師評級是多少?

The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by Cantor Fitzgerald, and Affimed reiterated their overweight rating.

阿基米德(納斯達克代碼:AFMD)的最新分析師評級由坎託·菲茨傑拉德提供,阿基米德重申其增持評級。

When is the next analyst rating going to be posted or updated for Affimed (AFMD)?

Affimed(AFMD)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Affimed的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Affimed的上一次評級是在2023年9月12日提交的,所以你應該預計下一次評級將在2024年9月12日左右提供。

Is the Analyst Rating Affimed (AFMD) correct?

分析師評級確認(AFMD)正確嗎?

While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Affimed (AFMD) is trading at is $0.50, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Affimed(AFMD)評級被重申,目標價在0.00美元至7.00美元之間。目前Affimed(AFMD)的交易價格為0.50美元,在分析師的預測範圍內。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論